302 related articles for article (PubMed ID: 33214722)
1. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Rakugi H; Yamakawa S; Sugimoto K
Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
[TBL] [Abstract][Full Text] [Related]
2. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
3. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
4. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
6. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
[TBL] [Abstract][Full Text] [Related]
8. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Wan N; Rahman A; Nishiyama A
J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
[TBL] [Abstract][Full Text] [Related]
11. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
[TBL] [Abstract][Full Text] [Related]
13. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
Sato A; Nishimoto M
Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
[TBL] [Abstract][Full Text] [Related]
17. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.
Janković SM; Janković SV
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):291-308. PubMed ID: 35190999
[TBL] [Abstract][Full Text] [Related]
20. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
